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Liver Fat and Cardiometabolic Risk 
Factors Among School-Age Children
Madelon L. Geurtsen,1,2 Susana Santos,1,2 Janine F. Felix,1-3 Liesbeth Duijts,2 Meike W. Vernooij,3,4 Romy Gaillard,1,2 and  
Vincent W.V. Jaddoe1-3
BaCKgRoUND aND aIMS: Nonalcoholic fatty liver 
disease is a major risk factor for cardiometabolic disease in 
adults. The burden of liver fat and associated cardiometabolic 
risk factors in healthy children is unknown. In a population-
based prospective cohort study among 3,170 10-year-old chil-
dren, we assessed whether both liver fat accumulation across 
the full range and nonalcoholic fatty liver disease are associ-
ated with cardiometabolic risk factors already in childhood.
appRoaCH aND ReSUltS: Liver fat fraction was meas-
ured by magnetic resonance imaging, and nonalcoholic fatty 
liver disease was defined as liver fat fraction ≥5.0%. We meas-
ured body mass index, blood pressure, and insulin, glucose, 
lipids, and C-reactive protein concentrations. Cardiometabolic 
clustering was defined as having three or more risk fac-
tors out of high visceral fat mass, high blood pressure, low 
high-density-lipoprotein cholesterol or high triglycerides, and 
high insulin concentrations. Nonalcoholic fatty liver disease 
prevalences were 1.0%, 9.1%, and 25.0% among children who 
were normal weight, overweight, and obese, respectively. Both 
higher liver fat within the normal range (<5.0% liver fat) and 
nonalcoholic fatty liver disease were associated with higher 
blood pressure, insulin resistance, total cholesterol, triglycer-
ides, and C-reactive protein concentrations (P values  <  0.05). 
As compared with children with <2.0% liver fat, children 
with ≥5.0% liver fat had the highest odds of cardiometabolic 
clustering (odds ratio 24.43 [95% confidence interval 12.25, 
48.60]). The associations remained similar after adjustment for 
body mass index and tended to be stronger in children who 
were overweight and obese.
CoNClUSIoNS: Higher liver fat is, across the full range 
and independently of body mass index, associated with an ad-
verse cardiometabolic risk profile already in childhood. Future 
preventive strategies focused on improving cardiometabolic 
outcomes in later life may need to target liver fat develop-
ment in childhood. (Hepatology 2020;72:119-129).
Nonalcoholic fatty liver disease is a major risk factor for cardiometabolic disease, end-stage liver disease, and subsequent need for 
liver transplantation.(1-4) In adults, nonalcoholic fatty 
liver disease is associated with cardiovascular disease, 
dyslipidemia, type 2 diabetes mellitus, and metabolic 
syndrome.(1,3,5,6) Because of high rates of childhood 
overweight and obesity, nonalcoholic fatty liver dis-
ease has become the most common chronic liver 
disease in children in Western countries.(3,7) The esti-
mated prevalence in children varies from 3% to 11%, 
depending on population characteristics and diag-
nostic methods.(2,8,9) Studies on the cardiometabolic 
consequences of nonalcoholic fatty liver disease in 
children are scarce. Studies in small population-based 
samples among children who were older or only 
obese suggested that nonalcoholic fatty liver disease 
is associated with increased risks of insulin resistance, 
hypertension, and dyslipidemia.(5,7,10-14) It is not 
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known whether liver fat also influences cardiometa-
bolic risk factors in children without obesity or non-
alcoholic fatty liver disease. The limited number of 
studies focused on liver fat in children is partly due 
to the difficulty in measuring liver fat. Liver biopsy 
is the gold standard for diagnosing nonalcoholic fatty 
liver disease, but is not possible to perform in pop-
ulation-based samples.(2,6) Magnetic resonance imag-
ing (MRI) enables noninvasive measurement of liver 
fat.(15,16)
We performed a cross-sectional analysis among 3,170 
10-year-old children participating in a population- 
based prospective cohort study to examine whether 
liver fat accumulation across the full range and nonal-
coholic fatty liver disease assessed with MRI are associ-
ated with cardiometabolic risk factors.
Patients and Methods
StUDy popUlatIoN
This study was embedded in the Generation R 
Study, a population-based prospective cohort from 
early fetal life onward, based in Rotterdam, the 
Netherlands.(17) The study has been approved by 
the Medical Ethical Committee of the Erasmus 
University Medical Center in Rotterdam (MEC 
198.782/2001/31). Written informed consent was 
obtained from parents for all participants.(17) All chil-
dren were born between April 2002 and January 2006. 
In total, 4,245 children attended the MRI subgroup 
study at 10  years. None of these children had a his-
tory of jaundice, medication use, alcohol use, smoking, 
or drugs, based on information from questionnaires 
at 10  years. We included children with at least one 
cardiometabolic outcome available. The population 
for analysis of this subgroup study comprised 3,170 
children (Supporting Fig. S1). Missing measurements 
were mainly due to no data on liver fat, MRI artifacts, 
or blood sampling.
lIVeR Fat at 10 yeaRS
We measured liver fat using a 3.0 Tesla MRI 
(Discovery MR750w, GE Healthcare, Milwaukee, 
WI).(15-18) The children wore light clothing without 
metal objects while undergoing the body scan. A liver 
fat scan was performed using a single-breath-hold, 3D 
volume and a special 3-point proton density weighted 
Dixon technique (IDEAL IQ) for generating a pre-
cise liver fat fraction image.(19) The IDEAL IQ scan 
is based on a carefully tuned 6-echo echo planar imag-
ing acquisition. The obtained fat-fraction maps were 
analyzed by Precision Image Analysis (PIA, Kirkland, 
WA) using the sliceOmatic (TomoVision, Magog, 
Canada) software package. All extraneous structures 
and any image artifacts were removed manually.(20) 
Liver fat fraction was determined by taking 4 sam-
ples of at least 4 cm2 from the central portion of the 
hepatic volume. Subsequently, the mean signal intensi-
ties were averaged to generate an overall mean liver fat 
estimation. Liver fat measured with IDEAL IQ using 
MRI is reproducible, highly precise, and validated in 
adults.(21,22) As described, nonalcoholic fatty liver dis-
ease was defined as liver fat ≥5.0%.(7,18,22) To study 
the associations across the full spectrum, liver fat was 
first categorized into six categories (0.0%-0.9%, 1.0%-
1.9%, 2.0%-2.9%, 3.0%-3.9%, 4.0%-4.9%, and >5.0%). 
Because only 5 children were in the 0.0%-0.9% group, 
we combined them with the 1.0%-1.9% group. In total 
5 categories were used: <2.0% (n = 1,590), 2.0%-2.9% 
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(n = 1,160), 3.0%-3.9% (n = 250), 4.0%-4.9% (n = 80), 
and ≥5.0% (n = 90). The reference group was <2.0% 
because it is the largest group and contains the median 
of the sample. Because of lower numbers, no further 
subcategories were possible for >5.0% liver fat.
CaRDIoMetaBolIC RISK 
FaCtoRS at 10 yeaRS
We measured blood pressure at the right brachial 
artery four times with 1-minute intervals using the 
validated automatic sphygmomanometer Datascope 
Accutor Plus (Paramus, NJ).(23) We calculated the 
mean value for systolic and diastolic blood pressure 
using the last three blood pressure measurements of 
each participant. Thirty-minute fasting venous blood 
samples were collected to measure glucose, insulin, 
total cholesterol, high-density lipoprotein (HDL) 
cholesterol, triglycerides and C-reactive protein 
concentrations.(17) We consider the 30-minute fast-
ing samples as nonfasting samples. This time inter-
val was chosen because of the design of our study, in 
which it was not possible to obtain fasting samples 
from all children. Glucose, total cholesterol, HDL 
cholesterol, C-reactive protein, and triglycerides 
concentrations were measured using the c702 
module on the Cobas 8000 analyzer. Insulin was 
measured with electrochemiluminescence immu-
noassay on the E411 module (Roche, Almere, the 
Netherlands). Concentrations of low-density lipo-
protein (LDL) cholesterol were calculated according 
to the Friedewald formula.(24) Insulin resistance was 
estimated with the homeostatic model assessment 
of insulin resistance (HOMA-IR) using the follow-
ing formula: insulin resistance  =  (insulin [μU/L]  ×   
glucose [mmol/L])/22.5.(25) Visceral fat mass was 
obtained by MRI scans, as described.(17,26) We 
defined children with clustering of cardiometabolic 
risk factors being at risk for metabolic syndrome phe-
notype, in line with other studies.(27,28) Clustering of 
cardiometabolic risk factors was defined as having 
three or more out of the following four adverse risk 
factors: visceral fat mass above the seventy-fifth per-
centile; systolic or diastolic blood pressure above the 
seventy-fifth percentile percentile; HDL cholesterol 
below the twenty-fifth percentile or triglycerides 
above the seventy-fifth percentile; and insulin above 
the seventy-fifth percentile of our study population.
CoVaRIateS
At enrollment in the study, we obtained maternal 
education level and prepregnancy weight by ques-
tionnaires, measured maternal height, and calculated 
prepregnancy body mass index (BMI). Information 
on child age and sex was obtained from medical 
records and on ethnicity from questionnaires. We 
measured childhood height and weight, both with-
out shoes and heavy clothing, calculated BMI at 
10  years, and further calculated sex-adjusted and 
age-adjusted childhood BMI standard deviation 
scores (SDS; Growth Analyzer 4.0, Dutch Growth 
Research Foundation).(29) Childhood BMI was cat-
egorized into underweight, normal weight, over-
weight, and obesity using the International Obesity 
Task Force cutoffs.(30)
StatIStICal aNalySIS
First, we examined differences in subject character-
istics between childhood BMI groups with analysis of 
variance tests for continuous variables and Chi-square 
tests for categorical variables. We used similar meth-
ods to assess the differences for cardiometabolic risk 
factors between children with and without nonalco-
holic fatty liver disease in children who were normal 
weight, overweight, and obese. For nonresponse anal-
yses, we compared participants and nonparticipants 
with Student t tests, Mann-Whitney tests, and Chi-
square tests.
Second, we used linear regression models to assess 
the associations of liver fat across the full range and 
nonalcoholic fatty liver disease, both compared with 
the reference group, with cardiometabolic risk factors 
at 10  years. Analyses were performed for the total 
group and also separately for children who were nor-
mal weight and overweight or obese, to whom we fur-
ther refer as children who are overweight.
Third, we used logistic regression models to assess 
the associations of liver fat in categories with the odds 
of adverse levels of single and clustered cardiometa-
bolic risk factors at 10  years. Only cases with com-
plete data on cardiometabolic outcomes were used 
for the analyses with clustered cardiometabolic risk 
factors. For all analyses, we presented a basic model 
adjusted for child age, sex, and ethnicity and a con-
founder model, which was additionally adjusted for 
maternal prepregnancy BMI and education. Because 
Hepatology, July 2020GEURTSEN ET AL.
122
we were interested in the associations of liver fat with 
cardiometabolic risk factors independently of BMI, 
we analyzed an extra model, which was additionally 
adjusted for child BMI at 10 years (BMI model), to 
observe the additional confounding effect of BMI 
in our associations. Covariates were included in the 
models based on other studies, strong correlations 
with liver fat, risk of nonalcoholic fatty liver dis-
ease and with cardiometabolic risk factors, and if 
they changed the effect estimates >10%.(2,8) Because 
insulin, HOMA-IR, triglycerides, and C-reactive 
protein concentrations were skewed, we used their 
natural logged values in all linear regression analyses. 
Because of a violation of the normality of the residu-
als assumption in the linear regression models, which 
was caused by a skewed distribution of liver fat, we 
also log-transformed liver fat when used continu-
ously. To enable comparison of effect sizes of differ-
ent measures, we constructed SDS ([observed value 
– mean]/SD) for all variables. We found a statistically 
significant interaction between liver fat and BMI for 
systolic blood pressure, HOMA-IR, triglycerides 
and C-reactive protein. No statistical interactions 
between liver fat and sex or between liver fat and 
ethnicity were observed in the associations with car-
diometabolic risk factors. As sensitivity analyses, we 
repeated the analyses with adjustment for visceral fat 
mass instead of BMI to explore whether any asso-
ciation was affected by visceral fat. Missing data of 
covariates were multiple-input using a Markov chain 
Monte Carlo approach. Five imput data sets were 
created and analyzed together. All statistical analy-
ses were performed using the Statistical Package of 
Social Sciences (SPSS) version 25.0 for Windows 
(IBM, Chicago, IL).
Results
SUBJeCt CHaRaCteRIStICS
The median liver fat fraction was 1.8% (95% range: 
1.1-3.1), 2.0% (95% range: 1.2-4.1), 2.5% (95% range: 
(1.4-8.7), and 3.1% (95% range: 1.7-17.9) in children 
who were underweight, normal weight, overweight, 
and obese, respectively (Table 1). Prevalences of non-
alcoholic fatty liver disease were 2.8% (n = 90) in the 
total group and 1.0% (n  =  26), 9.1% (n  =  41), and 
25.0% (n = 23) in children who were normal weight, 
overweight, and obese, respectively. We observed in 
all BMI groups higher levels of adverse cardiometa-
bolic risk factors in children with nonalcoholic fatty 
liver disease, compared with those without nonalco-
holic fatty liver disease (Table 2). Nonresponse analy-
ses showed that participants were slightly more often 
European and had lower BMI compared with non-
participants (Supporting Table S1).
lIVeR Fat aND 
CaRDIoMetaBolIC RISK 
FaCtoRS
Higher liver fat and nonalcoholic fatty liver dis-
ease were associated with higher systolic and diastolic 
blood pressure, HOMA-IR, and total cholesterol, 
triglycerides, and C-reactive protein concentrations 
(P values < 0.05; Fig. 1). As compared with the refer-
ence group of children with <2.0% of liver fat, children 
with ≥5.0% of liver fat tended to have the strongest 
associations with the cardiometabolic risk factors (dif-
ferences for systolic blood pressure (0.76 [95% confi-
dence interval {CI} 0.55-0.97] SDS), diastolic blood 
pressure (0.41 [95% CI 0.19-0.62] SDS), HOMA-IR 
(0.41 (95% CI 0.16-0.67) SDS, total cholesterol (0.51 
[95% CI 1.24-3.67] SDS), triglycerides (0.81 [95% 
CI 0.56-1.07] SDS), and C-reactive protein (1.06 
[95% CI 0.81-1.31] SDS). Supporting Fig. S2 shows 
similar results for the basic models. These associations 
of liver fat and nonalcoholic fatty liver disease with 
cardiometabolic risk factors were also present after 
additional adjustment for childhood BMI (Supporting 
Fig. S3). Liver fat and nonalcoholic fatty liver disease 
were positively associated with insulin and LDL cho-
lesterol and negatively associated with HDL choles-
terol and no associations were observed with glucose 
(Supporting Table S2). Stratified analyses showed that 
the associations of liver fat and nonalcoholic fatty liver 
disease with cardiometabolic outcomes were pres-
ent among both children who were normal weight 
and those who were overweight, with a tendency for 
stronger effect estimates among children who were 
overweight (Supporting Table S3). The sensitivity 
analyses using visceral fat instead of BMI showed no 
consistent differences in associations of liver fat and 
nonalcoholic fatty liver disease with cardiometabolic 
risk factors (Supporting Table S4).
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lIVeR Fat aND ClUSteRINg 
oF CaRDIoMetaBolIC RISK 
FaCtoRS
In children with nonalcoholic fatty liver dis-
ease, the prevalence of cardiometabolic clustering 
was 66.7% (n  =  30) compared with a prevalence of 
12.0% (n  =  224) in children without nonalcoholic 
fatty liver disease. Supporting Figs. S4 and S5 show 
liver fat continuously with cardiometabolic clustering 
present and not present, respectively. Higher liver fat 
was associated with higher odds of cardiometabolic 
clustering, already from a liver fat fraction of ≥2.0% 
onward (P values  <  0.05; Fig. 2). As compared with 
the reference group of children with <2.0% of liver 
fat, children with ≥5.0% of liver fat had the highest 
odds of cardiometabolic clustering (odds ratio [OR] 
24.43 [95% CI 12.25-48.60]). The strongest asso-
ciation for liver fat was observed with high visceral 
fat mass, with an OR 27.80 (95% CI 14.50-53.30; 
Supporting Fig. S7). Supporting Fig. S6 shows sim-
ilar results for the basic models and the associations 
were not materially affected after further adjustment 
for childhood BMI (Supporting Fig. S8). Because of 
the moderate correlation between liver fat and visceral 
fat, we also performed the analyses for the cardiomet-
abolic clustering excluding visceral fat; these showed 
slightly smaller but still statistically significant odds 
ratios (Supporting Table S5).
Discussion
We observed that not only nonalcoholic fatty liver 
disease but also a higher liver fat across the full range 
is associated with an adverse cardiometabolic profile in 
school-age children. Adverse cardiometabolic clustering 
was already observed from a liver fat fraction of ≥2.0% 
onward. The associations were independent of BMI and 
tended to be stronger in children who were overweight 
and obese than in children who were normal weight.
INteRpRetatIoN oF MaIN 
FINDINgS
Nonalcoholic fatty liver disease has a prevalence of 
up to 30% in the general adult population.(6,31) Because 
of the high rates of childhood overweight and obesity, 
nonalcoholic fatty liver disease has also become the 
ta
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most common chronic liver disease in children in the 
developed world.(3,18) Studies in selected populations 
estimated childhood prevalences of nonalcoholic fatty 
liver disease between 3% and 11%. The differences 
in prevalences were mainly due to heterogeneity in 
sample selection and diagnostic methods.(2,8,9) In a 
population-based sample, using a sensitive imaging- 
based method for liver fat assessment, we observed 
a prevalence of 2.8% for nonalcoholic fatty liver dis-
ease in all children, with the highest prevalence up to 
25.0% among children who were obese. Nonalcoholic 
fatty liver disease was not only present among chil-
dren who were obese but also among children who 
were normal weight. This high prevalence of nonal-
coholic fatty liver disease in 10-year-old children is an 
important population health problem.
FIg. 1. Associations of liver fat fraction and nonalcoholic fatty liver disease with cardiometabolic risk factors at school age. Values are 
regression coefficients (95% CI) from linear regression models that reflect differences in childhood cardiometabolic risk factors in SDS per 
SDS change in childhood liver fat fraction as compared with the reference group (children with <2.0% of liver fat; left side of each graph) 
or for children with nonalcoholic fatty liver disease as compared with the reference group (children with <5.0% of liver fat; right side of 
each graph). Associations are adjusted for child’s age, sex, ethnicity, maternal prepregnancy BMI, and maternal education. Trend lines are 
given only when P value for linear trend <0.05.
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Nonalcoholic fatty liver disease is strongly asso-
ciated with cardiovascular disease, dyslipidemia, and 
type 2 diabetes mellitus in adults.(1,3,5,18) A cross- 
sectional study in 571 children who were obese aged 
8-18  years showed that, as compared with children 
without nonalcoholic fatty liver disease, those with 
nonalcoholic fatty liver disease had higher BMI, 
insulin resistance, and triglycerides concentrations.(5) 
Three case-control studies reported that children with 
nonalcoholic fatty liver disease had a more adverse 
cardiometabolic profile.(11,12,14) In line with these pre-
vious studies, we observed that nonalcoholic fatty liver 
disease was associated with higher blood pressure, 
insulin resistance, adverse lipids profile, and increased 
C-reactive protein concentrations at 10 years.
To the best of our knowledge, no previous studies 
have assessed the associations of liver fat accumula-
tion across the full range. The cutoff point for defin-
ing nonalcoholic fatty liver disease in children and 
adults is originally derived from adult studies.(22) We 
observed that children with liver fat of ≥5.0% had the 
highest odds of cardiometabolic risk factor clustering. 
However, we also observed that even small increases 
in liver fat from ≥2.0% onward were associated with 
adverse cardiometabolic risk factors. Our results sug-
gest that in children, the cutoff for increased risk of an 
adverse cardiometabolic risk profile is already between 
2.0% and 3.0% liver fat, instead of the current cutoff 
of ≥5%. We could not test a lower cutoff because in 
our study group, only 5 children had liver fat <1.0%. 
These findings suggest that diagnosing nonalcoholic 
fatty liver disease in children might need a lower 
threshold than 5.0% liver fat. Current conventional 
ultrasounds cannot measure this low liver fat percent-
age, but future improvements in resolution of ultra-
sound techniques may enable detection of lower fat 
percentages. We also observed that the associations of 
liver fat with cardiometabolic risk factors in childhood 
were independent of BMI and present among both 
children who were normal weight and overweight, 
with stronger effect estimates among children who 
were overweight. The combination of higher liver fat 
FIg. 2. Associations of liver fat fraction and nonalcoholic fatty liver disease with odds of clustering of cardiometabolic risk factors at 
school age. Values are ORs (95% CI) analyzed in a subgroup of cases with complete data for all cardiometabolic variables (n = 1,906) that 
reflect the risk of cardiometabolic clustering per increase in liver fat fraction as compared with the reference group (<2.0%; left side of the 
figure) or for children with nonalcoholic fatty liver disease as compared with the reference group (children with <5.0% of liver fat; right 
side of the figure). Bars represent the percentage of cardiometabolic clustering per liver fat fraction group. Cardiometabolic clustering was 
defined as having three or more risk factors (high [greater than seventy-fifth percentile] visceral fat mass, high [greater than seventy-fifth 
percentile] systolic or diastolic blood pressure, low [less than twenty-fifth percentile] HDL cholesterol or high [greater than seventy-fifth 
percentile] triglycerides, and high [greater than seventy-fifth percentile] insulin. Associations are adjusted for child age, sex, ethnicity, 
maternal prepregnancy BMI, and maternal education. Trend lines are given only when P value for linear trend <0.05.
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and higher BMI might exacerbate the adverse car-
diometabolic health profile. Next to BMI, visceral fat 
is also known to correlate with liver fat.(26) However, 
our results suggest that the associations of liver fat 
with cardiometabolic risk factors were independent of 
visceral fat. Thus, not only nonalcoholic fatty liver dis-
ease but also small increases in liver fat accumulation 
within the normal range are, independent of BMI and 
visceral fat, related to an adverse cardiometabolic risk 
profile already in childhood.
The directions of the associations of liver fat with 
cardiometabolic risk factors cannot be concluded 
from a cross-sectional analysis. Future prospec-
tive follow-up studies should explore prospectively 
whether liver fat in childhood leads to increased 
risks of cardiovascular disease. In our study, we will 
perform follow-up studies in cardiovascular risk fac-
tors at age 18  years. Several mechanisms have been 
described linking liver fat with cardiometabolic risk 
factors.(4) Increased visceral fat mass may alter lipid 
metabolism and trigger insulin resistance that may 
subsequently lead to nonalcoholic fatty liver dis-
ease and cardiovascular disease.(4,32,33) On the other 
hand, liver fat can be the source of systemic release 
of inflammatory cytokines and proatherogenic factors 
leading to cardiometabolic diseases, including hyper-
tension.(3,4,26,33) Findings from other studies suggest 
a strong association of nonalcoholic fatty liver disease 
with the metabolic syndrome.(4,33) Also, studies in 
both adults and children showed associations of non-
alcoholic fatty liver disease with hypertension as part 
of the metabolic syndrome.(34-36) Adults with nonal-
coholic fatty liver disease had increased carotid artery 
intima-media thickness and increased prevalence of 
carotid atherosclerotic plaques.(35) Possible underlying 
mechanisms may include chronic inflammation lead-
ing to proatherogenic factors leading to arterial dam-
age and hypertension.(33) The strong associations of 
higher liver fat with both systolic blood pressure and 
C-reactive protein in our study support this hypoth-
esis. Prospective analyses or mendelian randomiza-
tion approaches may help to elucidate the directions 
of the observed associations. Our study suggests that 
increased levels of liver fat are common and associ-
ated with harmful cardiometabolic consequences in 
 childhood, predisposing children to cardiovascular 
disease later in life. Future studies should focus on 
specific lifestyle-related factors influencing liver fat 
from early childhood onward.
MetHoDologICal 
CoNSIDeRatIoNS
Major strengths of this study are the cross-sectional 
analysis performed in an ongoing prospective cohort 
study with a large sample size, with information on 
liver fat fraction measured with MRI and on car-
diometabolic outcomes in children at a young age.
The nonresponse at MRI visit would lead to biased 
effect estimates if associations were different between 
those included and not included in the analyses, but 
this seems unlikely. We had a relatively small number 
of children with obesity, which indicates a selection 
toward a lean population that might affect the gen-
eralizability of our findings. The healthy and young 
study population possibly also explains the small num-
ber of children with liver fat fraction above the clinical 
cutoff of 5.0%. This might have limited our statistical 
power to detect significant associations. However, little 
data are available on liver fat in healthy children and 
its relation to cardiometabolic risk factors. The fasting 
time before blood sampling was limited to 30 minutes, 
and thus we consider our samples nonfasting sam-
ples.(17) The blood samples were collected at different 
time points during the day, depending on the time of 
the study visit. Because glucose and insulin levels shift 
very easily during the day and are sensitive toward 
carbohydrate intake, this may have led to nondiffer-
ential misclassification of children with high or low 
glucose and insulin levels and thus underestimation of 
the observed effect estimates. On the other hand, for 
lipid levels, it has been shown that nonfasting blood 
sampling is superior to fasting in accurately predict-
ing cardiometabolic events for adults in later life.(37) 
Therefore, we believe our findings for triglycerides 
and cholesterol are less likely influenced by the non-
fasting state. Overall, these results need to be carefully 
interpreted, and further studies are needed to replicate 
our findings with fasting blood samples in children. 
Because we had a young study population, our results 
are not likely biased by alcohol use, known history 
of jaundice, hepatitis, smoking, drugs, or medication 
use. We had no data available on Tanner stages. The 
pubertal increase of sex hormones may be important 
in predisposition for nonalcoholic fatty liver disease.(38) 
In our population, we did not observe sex differences, 
possibly because of the young age. Although many 
covariates were included, there still might be some 
residual confounding, as in any observational study.
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Liver fat across the full range is associated with an 
adverse cardiometabolic risk profile already in chil-
dren of school age. The associations were independent 
of BMI and tended to be stronger in children who 
were overweight and obese. Future preventive strate-
gies focused on improving cardiometabolic outcomes 
in later life may need to target liver fat metabolism 
already in young childhood.
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